Matching COVID-19 Testing to Patient Needs in the New Phase of the Epidemic

Wednesday, July 27
3:30 – 4:30 p.m.
Exhibit Hall Theater 1
Supported by Abbott


Diagnostic testing has been an indispensable tool in the fight against COVID-19.  Since the infectious period is limited to the first five to ten days of the infection, prompt results are needed to change behaviors to limit transmission.  Laboratory testing provides high sensitivity but can sometimes have extended turn-around times.  For patients with milder symptoms who show up at physician offices and urgent care clinics, point-of-care molecular tests can provide immediate results to allow faster treatment decisions.  Meanwhile, routine serial antigen tests have allowed schools and businesses to get back to face-to-face meetings and travel to resume.


After attending this session, participants will be able to:

  • Highlight situational rapid testing needs as the world transitions into the next stage of the pandemic.
  • Differentiate rapid diagnostic tools and the value for acute and non-acute respiratory infections.
  • Discuss best practices for integrating rapid testing into workflows.


John Hackett
DVP Applied Research and Technology


Sheldon Campbell, MD, PhD, FCAP
Professor of Laboratory Medicine
Yale School of Medicine

Deborah L. Birx, M.D.
Senior Fellow 
George W. Bush Institute